Humanin variant P3S is associated with longevity in APOE4 carriers and resists APOE4-induced brain pathology.
Miller. Brendan B; Kim. Su-Jeong SJ; Cao. Kevin K; Mehta. Hemal H HH; Thumaty. Neehar N; Kumagai. Hiroshi H; Iida. Tomomitsu T; McGill. Cassandra C; Pike. Christian J CJ; Nurmakova. Kamila K; Levine. Zachary A ZA; Sullivan. Patrick M PM; Yen. Kelvin K; Ertekin-Taner. Nilüfer N; Atzmon. Gil G; Barzilai. Nir N; Cohen. Pinchas P
Key Findings
- Humanin P3S is enriched in centenarians who carry the APOE4 risk allele
- P3S binds strongly to APOE4 and reduces amyloid‑beta plaques in an APOE4‑mouse model
- Treatment with P3S up‑regulates genes involved in amyloid‑beta phagocytosis, both in mice and human brain tissue
Practical Outcomes
- The findings hint that boosting humanin, especially the P3S variant, could someday help APOE4 carriers protect brain health, but there’s no approved supplement or dosage yet. For now, biohackers should view this as a promising target for future research rather than a ready‑to‑use protocol.
Summary
A special form of the tiny protein humanin, called P3S, is found more often in very old people who carry the APOE4 gene, which usually raises Alzheimer risk. In mice that mimic APOE4‑related brain disease, giving this P3S version lowered harmful amyloid‑beta buildup and boosted the brain’s ability to clear it away. Human brain data also showed that higher humanin levels link to genes that help clean up amyloid. While promising, the research is still early and done in animals, not humans.
Abstract
The APOE4 allele is recognized as a significant genetic risk factor to Alzheimer's disease (AD) and influences longevity. Nonetheless, some APOE4 carriers exhibit resistance to AD even in advanced age. Humanin, a mitochondrial-derived peptide comprising 24 amino acids, has variants linked to cognitive resilience and longevity. Our research uncovered a unique humanin variant, P3S, specifically enriched in centenarians with the APOE4 allele. Through in silico analyses and subsequent experimental validation, we demonstrated a strong affinity between humanin P3S and APOE4. Utilizing an APOE4-centric mouse model of amyloidosis (APP/PS1/APOE4), we observed that humanin P3S significantly attenuated brain amyloid-beta accumulation compared to the wild-type humanin. Transcriptomic assessments of mice treated with humanin P3S highlighted its potential mechanism involving the enhancement of amyloid beta phagocytosis. Additionally, in vitro studies corroborated humanin P3S's efficacy in promoting amyloid-beta clearance. Notably, in the temporal cortex of APOE4 carriers, humanin expression is correlated with genes associated with phagocytosis. Our findings suggest a role of the rare humanin variant P3S, especially prevalent among individuals of Ashkenazi descent, in mitigating amyloid beta pathology and facilitating phagocytosis in APOE4-linked amyloidosis, underscoring its significance in longevity and cognitive health among APOE4 carriers.
Study Information
pubmed
2024
2024-03-22T00:00:00.000Z
10.1111/acel.14153
11
44